Back to discover
Drug

Ketanserin

In clinical development
Emerging researchLate-stage development

Also known as ketanserina.

1
Research papers
1
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

The Neurobiological Effect of 5-HT2AR Modulation

Clinical trial2024-12-16Results expected Q2 2030 · ClinicalTrials.gov

Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects.

Research2020-10-15Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology

Ketanserin Effects on Peripheral Temperature and Lactate (KoPTaL)

Clinical trial2019-04-01Primary completion · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Ketanserin
Aliases & brands
ketanserina
RxNorm CUI
6131
ChEMBL ID
CHEMBL51
ATC codes
C02KD01
UNII
97F9DE4CT4

Clinical trials

7 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
7
registered trials across all phases
LATEST COMPLETION 2021
1
Active studies
1
Recruiting
4
Late-stage (III+)
4
Completed
2
Discontinued
PHASE DISTRIBUTIONn = 7
Phase 12Phase 1 / 21Phase 32Phase 41Phase N / A1

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021 · 183 cites
Recent papers

Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021 · 183 cites
Major research themes2
Hallucinogens1Lysergic Acid Diethylamide1
Journals, researchers & institutions
Top journals
  • Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology1
Leading researchers
  • Borgwardt S1
  • Dolder P1
  • Duthaler U1
  • Eckert A1
  • Holze F1
  • Ley L1
  • Liechti ME1
  • Müller F1
Leading institutions
free-text, unnormalised
  • Department of Biomedicine and Department of Clinical Research1
  • Psychiatric University Hospital1
  • University of Basel1

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Frequently co-studied with Ketanserin in the research literature.

1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials